We are pleased to announce a new study for glaucoma, more specifically, mild or moderate primary open-angle glaucoma.  This study is for people that are between the ages of 18 and 85 and need cataract surgery. In this study we’ll use a biodegradable, extended-release implant as an alternative to glaucoma drops. This treatment has the potential to significantly limit disease progression and vision loss.

Glaucoma affects more than three million Americans over the age of 19 and is the leading cause of blindness in adults over 60.